Perrigo (NYSE:PRGO) has earned a consensus rating of “Hold” from the nineteen research firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $93.44.
A number of equities analysts recently weighed in on the stock. Canaccord Genuity set a $105.00 price objective on shares of Perrigo and gave the company a “buy” rating in a research report on Monday, April 16th. Oppenheimer set a $98.00 price target on Perrigo and gave the stock a “buy” rating in a research report on Monday, March 5th. Finally, Cantor Fitzgerald set a $107.00 price target on Perrigo and gave the stock a “buy” rating in a research report on Thursday, December 28th.
Shares of PRGO traded up $0.33 during mid-day trading on Wednesday, reaching $81.87. 257,950 shares of the stock traded hands, compared to its average volume of 1,009,888. The firm has a market capitalization of $11,483.57, a P/E ratio of 16.69, a price-to-earnings-growth ratio of 2.02 and a beta of 0.76. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.96 and a quick ratio of 1.40. Perrigo has a 1 year low of $63.68 and a 1 year high of $95.93.
Perrigo (NYSE:PRGO) last released its quarterly earnings results on Thursday, March 1st. The company reported $1.28 EPS for the quarter, beating analysts’ consensus estimates of $1.25 by $0.03. Perrigo had a net margin of 2.42% and a return on equity of 11.54%. The firm had revenue of $1.28 billion during the quarter, compared to analyst estimates of $1.26 billion. During the same period in the previous year, the business earned $1.24 EPS. The business’s revenue for the quarter was down 3.6% on a year-over-year basis. analysts expect that Perrigo will post 5.23 earnings per share for the current year.
In other news, CEO Uwe Roehrhoff purchased 7,500 shares of the company’s stock in a transaction that occurred on Monday, March 5th. The shares were acquired at an average cost of $81.85 per share, with a total value of $613,875.00. Following the transaction, the chief executive officer now owns 4,900 shares in the company, valued at approximately $401,065. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 6.90% of the company’s stock.
Several hedge funds have recently bought and sold shares of PRGO. Clal Insurance Enterprises Holdings Ltd lifted its position in Perrigo by 356.7% during the fourth quarter. Clal Insurance Enterprises Holdings Ltd now owns 1,436,621 shares of the company’s stock valued at $125,216,000 after purchasing an additional 1,122,068 shares during the period. Victory Capital Management Inc. lifted its position in Perrigo by 90.5% in the fourth quarter. Victory Capital Management Inc. now owns 2,046,980 shares of the company’s stock valued at $178,414,000 after buying an additional 972,210 shares during the last quarter. Systematic Financial Management LP acquired a new position in Perrigo in the fourth quarter valued at about $36,866,000. Renaissance Technologies LLC lifted its position in Perrigo by 289.2% in the fourth quarter. Renaissance Technologies LLC now owns 448,408 shares of the company’s stock valued at $39,083,000 after buying an additional 333,200 shares during the last quarter. Finally, Millennium Management LLC lifted its position in shares of Perrigo by 23.5% during the fourth quarter. Millennium Management LLC now owns 1,478,782 shares of the company’s stock worth $128,891,000 after purchasing an additional 281,267 shares in the last quarter. 79.09% of the stock is currently owned by institutional investors and hedge funds.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.